Research prototype, not medical advice.

In older people, a rapamycin analogue (everolimus) improves vaccine response and TORC1 inhibition reduces infections; small sample sizes.

Confidence
Debated
Level of evidence
Randomized clinical trial
Observed in
Human
Mission
Map of aging (12 hallmarks)
Concepts
Disabled macroautophagyRapamycin (and analogues: everolimus)mTOR (mTORC1)

What the sources say

Each row is an article. “Supports”: it backs the claim. “Contradicts”: it goes against it. “Qualifies”: it limits it (another species, a weaker effect…).

DirectionSourceWhere in the articleStatus
Supports Targeting the biology of ageing with mTOR inhibitors to improve immune function in older adults: phase 2b and phase 3 randomised trials
Mannick et al. · The Lancet Healthy Longevity 2021
— Verified
Supports TORC1 inhibition enhances immune function and reduces infections in the elderly
Mannick et al. · Science Translational Medicine 2018
— Verified
Supports mTOR inhibition improves immune function in the elderly
Mannick et al. · Science Translational Medicine 2014
— Verified